Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19.
Christophe AllaisDavid BernhardsonAdam R BrownGary M ChinigoJean-Nicolas DesrosiersKenneth J DiRicoIan HothamBrian P JonesSamir A KulkarniChad A LewisRicardo LiraRichard P LoachPeter D MorseJames J MousseauMatthew A PerryZhihui PengDavid W PlaceAnil M RaneLacey SampRobert A SingerZheng WangGerald A WeisenburgerHatice G YaylaJoseph M ZanghiPublished in: Organic process research & development (2023)
Lufotrelvir was designed as a first in class 3CL protease inhibitor to treat COVID-19. Development of lufotrelvir was challenged by its relatively poor stability due to its propensity to epimerize and degrade. Key elements of process development included improvement of the supply routes to the indole and lactam fragments, a Claisen addition to homologate the lactam, and a subsequent phosphorylation reaction to prepare the prodrug as well as identification of a DMSO solvated form of lufotrelvir to enable long-term storage. As a new approach to preparing the indole fragment, a Cu-catalyzed C-O coupling using oxalamide ligands was demonstrated. The control of process-related impurities was essential to accommodate the parenteral formulation. Isolation of an MEK solvate followed by the DMSO solvate ensured that all impurities were controlled appropriately.